Michael Casser, MD
Internal Medicine · New Milford, NJNPI 1972667723
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,032 of the $1,169 with a category attached, or 88.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.
Across 45 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$244
- Novo Nordisk$210
- Sanofi-aventis U.S. LLC$189
- AstraZeneca$122
- BD$88
- Lilly USA, LLC$72
- plus $246 from 7 others
Across 55 payments — averaging $40,405 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- BD$2.2M
- C. R. Bard, Inc. & Subsidiaries$7K
- Agile Therapeutics, Inc.$1K
What the payments were for
- Speaking & faculty fees$13812%
- Food & beverage$1,03288%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 2 | $244 |
| Novo Nordisk | 8 | $210 |
| Sanofi-aventis U.S. LLC | 12 | $189 |
| AstraZeneca | 1 | $122 |
| BD | 1 | $88 |
| Lilly USA, LLC | 4 | $72 |
| Pfizer | 4 | $65 |
| GSK | 4 | $55 |
| Mallinckrodt Hospital Products Inc. | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Boston Scientific | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,169 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $68,446 |
| EliquisApixaban | 57 | $55,103 |
| JanuviaSitagliptin Phosphate | 30 | $22,580 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $16,354 |
| VascepaIcosapent Ethyl | 32 | $10,904 |
| DenavirPenciclovir | 13 | $10,268 |
| JardianceEmpagliflozin | 11 | $8,431 |
| RestasisCyclosporine | 12 | $7,795 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $6,808 |
| BrilintaTicagrelor | 13 | $5,779 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,159 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $4,857 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $4,139 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,119 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $210 | $68,44663 claims |
| PfizerEliquis, Dilantin | $65 | $57,43669 claims |
| GSKAnoro Ellipta, Breo Ellipta | $55 | $23,16253 claims |
| AstraZenecaBrilinta, Symbicort | $122 | $8,89824 claims |
| Sanofi-aventis U.S. LLCLantus | $189 | $2,71415 claims |
| Lilly USA, LLCInsulin Lispro | $72 | $98114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in New Milford
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.